Insmed Jumps on ‘Blowout’ Gross sales Beat for Bronchiectasis Drug Brinsupri

Insmed set Wall Avenue abuzz with new gross sales figures for its newly-approved bronchiectasis drug Brinsupri that almost tripled consensus expectations.

In reporting preliminary outcomes for the yr, Insmed introduced Friday that Brinsupri introduced in $144.6 million within the fourth quarter 2025, its first full quarter since launching. That’s nearly thrice analyst expectations of $57.6 million. Calling the outcomes a “blowout gross sales efficiency,” analysts at William Blair stated in a Friday morning word that they’ve “elevated confidence within the drug’s multi-blockbuster gross sales potential long-term.”

Different analysts echoed the sentiment. “$144.6M??” Guggenheim Companions wrote, including that the determine blew previous even the $75 million “that we imagine the buyside hoped to see.”

In accordance with William Blair, the overperformance was largely pushed by 9,000 new sufferers beginning up on Brinsupri within the fourth quarter, including to the roughly 2,550 sufferers that began on the drug in its launch within the third quarter final yr.

Shares of Insmed are up about 8% to $183.80 in Friday morning buying and selling.

Over at Truist, analysts estimated that the whole affected person rely for Brinsupri is round 11,500, pacing about three quarters forward of the agency’s projections for including new prescriptions. Truist had anticipated Brinsupri to get to 9,950 sufferers by the second quarter of 2026 and 12,650 sufferers by the third quarter.

The FDA authorised Brinsupri in August 2025 for day by day therapy of non-cystic fibrosis bronchiectasis in adults and youngsters 12 years and up. On the time, analysts at Guggenheim wrote that they anticipated gross sales might hit $7.3 billion yearly by 2033. In accordance with Insmed, the whole addressable affected person inhabitants is round 500,000 within the U.S. The drug carries a price ticket of $88,000 per yr.

Insmed additionally reported different beats within the report, with the inhalable mycobacterium antibiotic Arikayce beating steering of $420 million to $430 million, raking in $433.8 million for the yr. That steering determine was raised in October 2025, from $405 million to $425 million, reflecting better-than-expected gross sales all year long.